Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
I'm LongbridgeAI, I can summarize articles.
Marker Therapeutics received a Buy rating from analyst Patrick Trucchio of H.C. Wainwright, with a $10 price target. This rating is based on promising Phase 1/2 data showing the effectiveness of its MAR-T cell platform in pancreatic cancer, demonstrating meaningful response rates and durable disease control. The proprietary product MT-601 has cleared FDA IND review for a Phase 1 study. Trucchio's analysis incorporates a risk-adjusted DCF framework, supporting the $10 target while acknowledging potential risks. Canaccord Genuity also maintains a Buy rating with an $8 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments